CD40 and neoplasm: Consequently, we find high numbers of intratumoral CD8+ T-lymphocytes after treatment with anti-CD40 antibodies in combination with sunitinib, associated with a significant reduction in tumor growth and increased survival of mice bearing either B16.F10 melanoma or T241 fibrosarcoma (Figure 1A-1D, Figure 4E-4F).